Celcuity (CELC) and Miragen Therapeutics (MGEN) Head to Head Survey

Celcuity (NASDAQ:CELC) and Miragen Therapeutics (NASDAQ:MGEN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability and analyst recommendations.

Earnings and Valuation

This table compares Celcuity and Miragen Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Celcuity N/A N/A -$6.25 million ($0.78) -34.49
Miragen Therapeutics $4.00 million 26.83 -$26.51 million ($1.38) -2.52

Celcuity has higher earnings, but lower revenue than Miragen Therapeutics. Celcuity is trading at a lower price-to-earnings ratio than Miragen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Celcuity and Miragen Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celcuity 0 0 2 0 3.00
Miragen Therapeutics 0 1 8 0 2.89

Celcuity presently has a consensus target price of $35.50, indicating a potential upside of 31.97%. Miragen Therapeutics has a consensus target price of $16.36, indicating a potential upside of 370.03%. Given Miragen Therapeutics’ higher probable upside, analysts plainly believe Miragen Therapeutics is more favorable than Celcuity.

Profitability

This table compares Celcuity and Miragen Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Celcuity N/A -24.34% -23.67%
Miragen Therapeutics -316.11% -48.03% -38.63%

Insider and Institutional Ownership

14.4% of Celcuity shares are held by institutional investors. Comparatively, 36.3% of Miragen Therapeutics shares are held by institutional investors. 43.5% of Celcuity shares are held by insiders. Comparatively, 18.9% of Miragen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Celcuity has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. Comparatively, Miragen Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500.

Summary

Celcuity beats Miragen Therapeutics on 7 of the 13 factors compared between the two stocks.

About Celcuity

Celcuity Inc., a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. The company is developing CELx tests to diagnose two new sub-types of HER2-negative breast cancer. It is also developing CELx tests to diagnose 14 new potential cancer sub-types in breast, lung, colon, ovarian, kidney, bladder, and hematological cancers. The company was founded in 2012 and is headquartered in Minneapolis, Minnesota.

About Miragen Therapeutics

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of microRNA-155, which is in Phase I clinical trial for treating cutaneous T-cell lymphoma; MRG-201, a replacement for microRNA-29, which is in Phase I clinical trial that is found at low levels in various pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, and pulmonary fibrosis, as well as systemic sclerosis; and MRG-110, an inhibitor of microRNA-92 that is expressed in endothelial cells and has shown to accelerate the formation of new blood vessels in preclinical models of heart failure, peripheral ischemia, and dermal wounding in the United States and Japan. The company also develops MRG-107, an inhibitor of miR-155 for treating neuronal amyotrophic lateral sclerosis, and other neurodegenerative indications, including spinal cord injury. It also develops preclinical product candidates for treating various indications, including oncology, visual pathologies, neurodegeneration, and hearing loss. Miragen Therapeutics, Inc. has a collaboration agreement with Les Laboratoires Servier and Institut de Recherches Servier for the development of MRG-110. The company was founded in 2006 and is based in Boulder, Colorado.

Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit